Definium Therapeutics (DFTX) Assets (2019 - 2026)

Definium Therapeutics (DFTX) has 8 years of Assets data on file, last reported at $401.3 million in Q1 2026.

• Quarterly Assets rose 45.75% year-over-year to $401.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $401.3 million (up 45.75% YoY) and the FY2025 annual result came in at $440.1 million, up 45.66% from the prior year.
• Assets retreated to $401.3 million in Q1 2026 per DFTX's latest filing, from $440.1 million in the prior quarter.
• Across five years, Assets topped out at $440.1 million in Q4 2025 and bottomed at $124.5 million in Q4 2023.
• The 5-year median for Assets is $236.9 million (2025), against an average of $234.3 million.
• The widest annual swing landed in 2022, when Assets sank 30.74%; it then soared 142.61% in 2024.
• Tracing DFTX's Assets over 5 years: stood at $170.0 million in 2022, then slipped by 26.74% to $124.5 million in 2023, then surged by 142.61% to $302.2 million in 2024, then jumped by 45.66% to $440.1 million in 2025, then retreated by 8.82% to $401.3 million in 2026.
• Per Business Quant, the three latest DFTX Assets figures stand at $401.3 million (Q1 2026), $440.1 million (Q4 2025), and $236.9 million (Q3 2025).

Peer Comparison